 |
Prospector
Profile
926-04
|
| |
| Hepalife Technologies, Inc. |
NAICS |
541710 |
| 60 State Street, Suite 700
Boston, MA 02109 |
Description |
Biotechnology |
| 1-800-518-4879 |
Employees |
5 |
| http://www.hepalife.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-4.6540 |
| |
Assets |
(mil) |
0.2790 |
| |
Liability |
(mil) |
1.3380 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Hepalife Technologies, Inc. had a net loss of $802,368 for the second quarter ended June 30, 2007, lower than the $1,437,396 net loss reported during the same quarter last year. For the six months ended June 30, 2007, the Company had a $1,541,348 net loss, lower than the $2,169,835 net loss reported in the first half of 2006. The Company's balance sheet showed an accumulated deficit of $12,757,220 as of June 30, 2007.
|
| |
|
Intellectual Property:
The Company is working towards optimizing the functionality of a chicken cell line, which is called the “PBS-1 Cell Line.” The PBS-1 Cell Line was developed for use in cell-based vaccine production and was exclusively licensed from the Michigan State University in June 2006. The license agreement gives HepaLife exclusive rights to five issued patents. [SEC Filing 10-K 04-02-07]
|
| |
|
Description:
The Company focuses on the identification and development of technologies and products for liver toxicity detection; products for the treatment of various forms of liver dysfunction and disease; and cell based technologies vaccine production.
|
| |
|
Officers:
Harmel S. Rayat (Chair, Sec., Treas. & CFO); Frank Menzler (Pres. & CEO); Javier Jimenez (Dir.)
|
| |
|
Auditor:
Peterson Sullivan PLLC
|
| |
|
Securities:
Common Stock-Symbol HPLF.OB; OTC BB;
73,926,276 common shares outstanding as of August 15, 2007.
|
| |
| |
| |
| return to main page |
|
|
